BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36206664)

  • 1. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
    Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
    Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
    Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
    Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
    Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
    Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
    Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
    J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
    Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
    ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.
    Zhang B; Li N; Gao J; Zhao Y; Jiang J; Xie S; Zhang C; Zhang Q; Liu L; Wang Z; Ji D; Wu L; Ren R
    J Exp Clin Cancer Res; 2024 Feb; 43(1):51. PubMed ID: 38373953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
    Li L; Li Y; Yang CH; Radford DC; Wang J; Janát-Amsbury M; Kopeček J; Yang J
    Adv Funct Mater; 2020 Mar; 30(12):. PubMed ID: 33071706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
    Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
    ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
    Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
    Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhu Q; Wang H; Chai S; Xu L; Lin B; Yi W; Wu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2216796120. PubMed ID: 36943877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
    Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
    Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle.
    Feng ZH; Li ZT; Zhang S; Wang JR; Li ZY; Xu MQ; Li H; Zhang SQ; Wang GX; Liao A; Zhang X
    Acta Biomater; 2021 Dec; 136():495-507. PubMed ID: 34619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.
    Wang H; Yao H; Li C; Shi H; Lan J; Li Z; Zhang Y; Liang L; Fang JY; Xu J
    Nat Chem Biol; 2019 Jan; 15(1):42-50. PubMed ID: 30397328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
    Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.